Atorvastatin News and Research

RSS

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Statins may have negative effects on some cardiac patients, says study

Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance.

4 Nov 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

Actavis' clients launch generic Atorvastatin in Spain

Actavis Group, the international generic pharmaceuticals company, today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market.

1 Oct 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks.

2 Sep 2009

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain.

1 Sep 2009

Nanofluidic biopsy detects subtle changes in cancer cells

By taking two standard laboratory techniques - capillary electrophoresis and antibody-based protein detection - and shrinking them to the nanoscale, researchers at the Stanford University School of Medicine have created a new method for detecting miniscule changes in the levels of proteins associated with cancer.

28 Jun 2009

Cholesterol-lowering statin drugs do not lower risk of pneumonia in seniors

Taking popular cholesterol-lowering statin drugs, such as Lipitor (atorvastatin), does not lower the risk of pneumonia. That's the new finding from a study of more than 3,000 Group Health patients published online on June 16 in advance of the British Medical Journal's June 20 print issue.

17 Jun 2009

Low blood pressure may increase risk of heart attack and stroke

Data from the Treating to New Targets (TNT) trial presented today at the American Society of Hypertension's Twenty Fourth Annual Scientific Meeting (ASH 2009) show that low blood pressure levels may lead to increased risk of cardiovascular events, including heart attack and stroke. These data supplement previous findings from the TNT trial of atorvastatin showing aggressive LDL cholesterol-lowering reduced cardiovascular events.

7 May 2009

Statins for the prevention of dementia

An increasing number of studies show that elevated serum cholesterol levels might be part of the cause of Alzheimer's disease, but a new review of studies says that, even so, the most successful class of cholesterol-lowering medicines will not stave off the condition.

14 Apr 2009

Rockefeller University Hospital opens clinical trial into statin-associated muscle complaints

The most widely prescribed class of drugs in the country, statins have helped millions of people lower their cholesterol and reduce their risk of heart attacks - but their side effects, including muscle pain and cramping, have proven to be something of a sore point for many patients.

14 Apr 2009

New alternative to biopsy detects subtle changes in cancer cells

A drop of blood or a chunk of tissue smaller than the period at the end of this sentence may one day be all that is necessary to diagnose cancers and assess their response to treatment, say researchers at the Stanford University School of Medicine.

12 Apr 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Atorvastatin News and Research

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Statins may have negative effects on some cardiac patients, says study

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Actavis' clients launch generic Atorvastatin in Spain

Combination of LIVALO and itraconazole drugs shows no adverse reactions

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

Nanofluidic biopsy detects subtle changes in cancer cells

Cholesterol-lowering statin drugs do not lower risk of pneumonia in seniors

Low blood pressure may increase risk of heart attack and stroke

Statins for the prevention of dementia

Rockefeller University Hospital opens clinical trial into statin-associated muscle complaints

New alternative to biopsy detects subtle changes in cancer cells

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Atorvastatin and lovastatin found to be ineffective for breast cancer prevention

Seniors warned about mixing OTC and prescription drugs

Metabolex announces positive results from phase 2 trial of MBX-8025

Cholesterol lowering drugs may protect against dementia

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News